Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 11/20 | 0.88 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | RPA1 | P27694 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893854 | 0.94 | MDM2 (0.77) | MDM2NOTUMAKR1C2AKR1C1PIN1 | |
| SCHEMBL28796347 | 0.94 | MDM2 (0.88) | MDM2NOTUMKMOHTR2AHTR2C | |
| SCHEMBL9893724 | 0.94 | MDM2 (1.00) | MDM2NOTUMKMOHTR2AHTR2C | |
| SCHEMBL1437176 | 0.93 | MDM2 (0.90) | MDM2NOTUMPIN1KMOHTR2A | |
| SCHEMBL1438150 | 0.93 | MDM2 (0.88) | MDM2NOTUMAKR1C2AKR1C1PIN1 | |
| SCHEMBL1437130 | 0.91 | MDM2 (0.86) | MDM2NOTUMKMOHTR2AHTR2C | |
| SCHEMBL9893785 | 0.90 | MDM2 (0.72) | MDM2AKR1C2AKR1C1PIN1KMO | |
| SCHEMBL27879077 | 0.88 | MDM2 (0.88) | MDM2NOTUMPIN1HTR2AHTR2C | |
| SCHEMBL9893873 | 0.88 | MDM2 (0.68) | MDM2 | |
| SCHEMBL9894206 | 0.88 | MDM2 (0.83) | MDM2AKR1C2AKR1C1PIN1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885NOTUM 4675/4885AKR1C2 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.